P. Wolkenstein
0000-0001-8194-457X
Publication & Citation Trends
Publications
0 total
Disease burden and unmet needs in adults with neurofibromatosis type 1 and plexiform neurofibromas: A systematic literature review
Cited by 0
Semantic Scholar
Clinical benefits of selumetinib in adults with neurofibromatosis type 1 - Authors' reply.
Cited by 0
Semantic Scholar
Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study.
Cited by 12
Semantic Scholar
Stigmatization related to cutaneous neurofibromas in neurofibromatosis 1: Development, validation and severity strata of the cNF-PUSH-D.
Cited by 0
Semantic Scholar
343P Breast cancers (BC) in a series of 140 women affected with neurofibromatosis 1 (NF1): Clinical and pathological characteristics, prognosis
Cited by 0
Semantic Scholar
[Neurofibromatosis type 1: recent advances].
Cited by 0
Semantic Scholar
Preformulation evaluation of selumetinib for topical application: skin distribution and photodegradation analysis using MALDI imaging and LC-MS/MS
Cited by 0
Semantic Scholar
Updated diagnostic criteria and nomenclature for Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation consensus recommendation
Cited by 1
Semantic Scholar
Research Topics
Neurofibromatosis and Schwannoma Cases
(254)
Drug-Induced Adverse Reactions
(166)
Autoimmune Bullous Skin Diseases
(110)
Urticaria and Related Conditions
(91)
Soft tissue tumor case studies
(74)
Affiliations
Université Paris-Sud
Délégation Paris 5
Northwestern University
University of Southern California
Roche (Switzerland)